Trials / Completed
CompletedNCT01774981
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this two-part study is to investigate the safety, tolerability and efficacy of LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy (DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate Proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered IV |
| DRUG | LY3016859 | Administered IV |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2013-01-24
- Last updated
- 2019-09-19
- Results posted
- 2017-08-15
Locations
7 sites across 2 countries: United States, Bulgaria
Source: ClinicalTrials.gov record NCT01774981. Inclusion in this directory is not an endorsement.